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ome pathogens can begin an infection with only a
small number of cells in the initial inoculum. For
example, enterohemorrhagic strains of Escherichia coli
require an infective dose of only about ten cells. By contrast,
other pathogens, such as Vibrio cholerae, require a large
number of cells (10
3 to 10
8 cells) in the inoculum to
successfully infect a host (Figure 1).
We propose a new hypothesis to explain the wide diversity
of infective dose among pathogens. In our hypothesis, the
biochemical mechanisms of pathogenesis, which typically
facilitate invasion by evading host immune defenses, explain
much of the variation in infective dose. If these pathogenic
mechanisms act locally, then we predict that the infective
dose will be low; if the pathogenic molecules tend to diffuse
and act at a distance, then we predict that the infective dose
will be high. Local action requires relatively few molecules
and therefore relatively few infecting cells. Distant action
requires that the infecting population of pathogens builds up
sufﬁcient quantities of diffusible molecules to achieve
sufﬁcient effect before the host can clear the infection (the
‘‘frontal attack strategy’’ described in [1]); thus, larger
infecting doses are required to produce sufﬁcient
concentrations of the diffusible pathogenic molecules. Few
standardized studies of infective dose have been conducted,
in part because there has never been a clear conceptual
framework within which to study the problem and formulate
testable predictions. To test our hypothesis, we therefore use
the reasonably standardized databases of the United States
Food and Drug Administration [2] and Health Canada [3],
supplemented by additional references.
The diverse and well-deﬁned secretion systems of bacteria
provide good contrasts between local and distant mechanisms
of pathogenesis. For local action, the upper part of Figure 1
shows several examples in which the bacteria either directly
transfer proteins into the host cells (via a type III secretion
system) or act via bacterial surface-bound molecules. Local
molecular mechanisms are illustrated by the following
examples [4,5]: Shigella infection depends on direct injection
of several bacterial proteins (invasion plasmid antigens) via a
type III secretion system [5], by which the host cell surface is
manipulated and the bacterium is taken up into a vacuole.
Enterohemorrhagic E. coli infects using a ‘‘attaching and
effacing’’ mechanism, which is mediated by an outer-
membrane protein (intimin) or by direct delivery of receptors
and proteins inducing host cell cytoskeleton changes [6].
Similarly, enteropathogenic E. coli relies on direct delivery of
receptors and additional proteins [4,6] by a type III secretion
system. The bacteria-produced receptor is delivered allowing
for the binding with further bacterial protein that
manipulates the host cell. Listeria monocytogenes invades cells of
intestinal mucosa or macrophages with the help of bacterial
membrane-bound proteins (internalins) [4,5,7]. Forced
phagocytosis puts the bacterium inside host cell vacuoles. The
other bacteria in the upper part of Figure 1 display similar
local action of pathogenesis.
The lower part of Figure 1 shows four cases of distant
action and, as we predict, relatively high numbers of
pathogens required in the inoculum to initiate an infection.
We classify the species as having distant action if a necessary
component of invasion and pathogenesis includes a secreted
factor that diffuses before exerting its pathogenic effect. This
may arise, for example, through immune modulators
delivered by the general secretory pathway, or the type I and
type II secretory systems in Gram-negative bacteria. For V.
cholerae, the action of the secreted cholera toxin is necessary
and likely to be the limiting step, even though the parasite
also uses a locally acting type IV secretion system that delivers
the bacteria-produced receptor for cholera toxin directly
into the host cell [4,5]. Infection by Bacillus anthracis depends
on the bacterial anthrax toxin, of which one essential
component (protective agent) is secreted by the bacteria.
After the protective agent diffuses and binds to receptors of
host immune cells, the other two components (lethal factor
and edema factor) are transported directly into host cells [8,9]
and help evade host immunity. Staphylococcus aureus has an
astonishing variety of both locally acting (surface-bound) and
secreted, diffusible factors; however, successful infection
requires sufﬁcient quantity of the initially secreted, immune-
modulating proteins [10]. Streptococcus pneumoniae relies on a
cytoplasmic protein secreted by a cell-bound autolysin,
inducing pore formation in host mucosal cells [5,11].
In this article, we emphasized the distinction between local
and distant action of pathogenic mechanisms with regard to
invasion and other criteria relevant for the observed dose-
response variation among pathogens. This distinction
between local and distant action may also explain some of the
differences between pathogens in the total amount of harm
(virulence) caused by infection. For example, all of the
pathogens listed in Figure 1 can cause severe disease, but it is
remarkable that those pathogens that secrete distantly acting
immune modulators include most of the extremely virulent
pathogens, such as B. anthracis or S. aureus. Hence, this
framework should also lead to a better understanding of the
evolution of virulence itself. Previously, no broadly applicable
and predictive hypothesis of infective dose existed, so few
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We present the examples in Figure 1 to illustrate our
hypothesis and to show that a preliminary survey supports the
predictions. With our clear predictions, new studies on
bacteria and on viruses can directly test the idea that local
versus distant action inﬂuences infective dose and
virulence. &
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Information on genetic sequences for the mentioned proteins can
be found in GenBank (http://www.ncbi.nlm.nih.gov/entrez/): Shigella
ﬂexeneri (IpaB, 1238055; IpaC, 1238054); Escherichia coli intimin
(915471); Listeria monocytogenes internalins (InlA, 985151; InlB, 98692);
Vibrio cholerae (O139, ctxA, ctxB: X76391); Bacillus anthracis (protective
agent, CDS AF306780; lethal factor, CDS AY997300; edema factor,
CDS AY997301); Streptococcus pneumoniae autolysin (933669).
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Figure 1. Dose and Mode of Pathogenic Mechanism
Upper panel: bacteria with pathogenic mechanisms that depend on direct contact (local action). Lower panel: bacteria with pathogenic mechanisms
that depend on secreted molecules (distant action). Dose information is from the US Food and Drug Administration [2] and Health Canada [3]. Various
sources include references [12–14]. Values for Yersinia are considered low by the US Food and Drug Administration, while Health Canada refers to LD50
in mice.
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